The Emerging Science of Fasting and Autoimmune Disease: A New Hope?
For decades, autoimmune diseases – conditions where the body’s immune system attacks its own tissues – have been managed primarily with immunosuppressant drugs. But a growing body of research, spearheaded by biogerontologist Valter Longo, PhD, suggests a potentially transformative approach: strategically timed cycles of fasting, or more precisely, a “fasting-mimicking diet.”
From Personal Observation to Scientific Inquiry
Longo’s journey into this field began with a personal observation. As a young man, he noticed a stark contrast in health outcomes between his relatives in Italy and those who had immigrated to the United States. Despite genetic similarities, the American relatives experienced higher rates of diabetes and cardiovascular disease, largely attributed to a Western diet high in fat, meat, and sugar. This sparked a lifelong interest in the interplay between diet, genetics, and disease.
The Jenni Russell Case: A Turning Point
In 2015, Longo received a desperate email from Jenni Russell, a journalist suffering from a severe autoimmune intestinal condition for 20 years. Her condition had worsened after chemotherapy, and she was reliant on four immunosuppressant medications. Despite the lack of human studies, Russell, exhausted and seeking alternatives, decided to try cycles of fasting based on Longo’s animal research. Remarkably, after four cycles of a 3-4 day fasting regimen, she was able to discontinue her medications and her symptoms disappeared.
How Does it Work? The Science Behind the Rapid
Longo’s research, initially conducted on animal models, demonstrated that cycles of fasting stimulate the activation of stem cells, promoting regeneration of the immune system. Subsequent studies on animals with autoimmune conditions similar to Crohn’s disease and ulcerative colitis showed that a “diet that mimics fasting” (DMF) had broader benefits than water-only fasting, partly due to the inclusion of prebiotics and their positive impact on the gut microbiome.
Clinical Trial Results: Promising Data Emerges
While laboratory studies and initial patient experiences were encouraging, rigorous clinical trials were needed. Recent studies are beginning to provide that evidence. A 2025 study at the University of Miami, involving 32 patients with ulcerative colitis, showed that two cycles of the DMF, combined with medication, led to significant improvement in 57% of patients, compared to 35% in the medication-only group.
Further bolstering these findings, a study at Stanford University, involving nearly 100 patients with Crohn’s disease, revealed that 64% of patients receiving both medication and the DMF achieved clinical remission – a substantial improvement over the 37% remission rate in the medication-only group. A key indicator, a reduction of at least 50% in fecal calprotectin (a marker of intestinal inflammation), was observed in 37% of the DMF group versus only 6% in the medication-only group.
Beyond Intestinal Diseases: A Broader Application?
The implications extend beyond inflammatory bowel diseases. The convergence of animal model data and human clinical results suggests that the DMF holds promise for a range of autoimmune conditions. However, Longo emphasizes that the benefits are likely temporary if the underlying causes of inflammation are not addressed. For example, a celiac patient achieving remission through DMF would still need to avoid gluten to maintain their health.
The Future of Fasting and Autoimmunity
The research is still evolving, but the potential is clear. Here’s what we can anticipate:
Standardization and Regulation
Longo advocates for the standardization and regulation of DMFs, treating them with the same rigor as pharmaceutical interventions. This would ensure quality control, appropriate dosage, and patient safety.
Personalized Fasting Protocols
Future research will likely focus on tailoring fasting protocols to individual needs, considering factors like genetics, disease severity, and overall health status. A “one-size-fits-all” approach may not be optimal.
Combination Therapies
DMFs are unlikely to replace conventional medications entirely. Instead, they are likely to be integrated into combination therapies, potentially reducing the dosage of immunosuppressants and minimizing their side effects.
Expanding the Scope of Research
Ongoing studies will explore the efficacy of DMFs for other autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and type 1 diabetes.
FAQ
Q: Is fasting safe for everyone with an autoimmune disease?
A: No. It’s crucial to consult with a healthcare professional before starting any fasting regimen, especially if you have an underlying medical condition or are taking medications.
Q: What is a “fasting-mimicking diet”?
A: It’s a five-day diet based on healthy, natural foods and ingredients designed to provide the benefits of fasting without complete food deprivation.
Q: Will fasting cure my autoimmune disease?
A: While promising, fasting is not a cure. It may help manage symptoms and potentially induce remission, but it’s unlikely to eliminate the underlying cause of the disease.
Q: How often should I do a fasting-mimicking diet?
A: The optimal frequency is still being researched. Current studies suggest cycles every few months, but this should be determined in consultation with a healthcare provider.
Did you know? Valter Longo’s research began with a simple observation about dietary differences and their impact on health, highlighting the power of everyday insights in driving scientific discovery.
Pro Tip: Before considering a fasting-mimicking diet, focus on establishing a healthy baseline diet rich in whole foods, fruits, vegetables, and lean protein.
Have you or someone you know explored fasting as a potential treatment for autoimmune disease? Share your experiences in the comments below!
Keep reading